Nantes, France – October 7, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), is pleased to announce the appointment of Dr. Nicolas Poirier as its new Chief Executive Officer effective today. This appointment follows the decision of the Board of Directors to end the mandate of Alexis Vandier.
Throughout his career, Dr. Nicolas Poirier has demonstrated both expertise as an international scientific leader, pioneer in the discovery and development of innovative immunotherapies, and in-depth knowledge of the challenges of the biotechnology sector through various management functions. strategic leadership. He played a decisive role in the development of OSE Immunotherapeutics, notably at the origin of 5 programs in the Company’s portfolio which are now at the clinical stage. He also strongly contributed to the signing of 4 strategic pharmaceutical partnerships for OSE Immunotherapeutics.